Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata

(2022) Brett King et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Two Phase 3 Trials of Baricitinib for Alopecia Areata

(2022) Brett King et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

(2021) Brett King et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata

(2021) Zhenpeng Dai et al.   JCI Insight

Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers

(2021) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

(2021) Brett King et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The Alopecia Areata Investigator’s Global Assessment (AA‐IGA™) Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials

(2020) K.W. Wyrwich et al.   BRITISH JOURNAL OF DERMATOLOGY

Hair follicle immune privilege and its collapse in alopecia areata

(2020) Marta Bertolini et al.   EXPERIMENTAL DERMATOLOGY

Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata

(2019) Isabelle A. Vallerand et al.   JAMA Dermatology

PF-06651600, a dual JAK3/TEC family kinase inhibitor

(2019) Hua Xu et al.   ACS Chemical Biology

Epidemiology of alopecia areata, ophiasis, totalis and universalis: A systematic review and meta-analysis

(2019) Harrison H. Lee et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children, and their families

(2018) Lucy Y. Liu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients

(2017) Lucy Y. Liu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition

(2016) Jean-Baptiste Telliez et al.   ACS Chemical Biology

Identification of Autoantigen Epitopes in Alopecia Areata

(2016) Eddy H.C. Wang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Multiplex matrix network analysis of protein complexes in the human TCR signalosome

(2016) Stephen E. P. Smith et al.   Science Signaling

Multiplex matrix network analysis of protein complexes in the human TCR signalosome

(2016) Stephen E. P. Smith et al.   Science Signaling

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

(2014) Luzhou Xing et al.   NATURE MEDICINE

Promotion and prevention of autoimmune disease by CD8+ T cells

(2013) David M. Gravano et al.   JOURNAL OF AUTOIMMUNITY

Alopecia Areata

(2012) Amos Gilhar et al.   NEW ENGLAND JOURNAL OF MEDICINE